DanielGomezMD

Thoracic Cancer

Physician

Overview of Dr. Gomez

Dr. Daniel Gomez is a radiation oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of California (San Francisco) School of Medicine and has been in practice 16 years. He is one of 106 doctors at Memorial Sloan Kettering Cancer Center and one of 26 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Radiation Oncology. He has more than 100 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(267) 460-0032

Education & Training

Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2005 - 2009
University of California San Francisco School of MedicineClass of 2004

Certifications & Licensure

FL State Medical License 2023 - Present
NY State Medical License 2005 - 2026
NJ State Medical License 2019 - 2025
TX State Medical License 2009 - 2020
American Board of Radiology Radiation Oncology

Clinical Trials

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2022 Jun 15
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study Start of enrollment: 2018 Jan 17
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2022 Dec 09
Recruiting
Phase 2
Roles: Contact

Publications & Presentations

PubMed

Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients.
Stijn Vanstraelen, Kay See Tan, Prasad S Adusumilli, Manjit S Bains, Matthew J Bott
Annals of Surgery. 2024-10-01
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
Si-Yang Liu, Tatiana Erazo, Justin Jee, Andrea Arfe, Avantika Gupta
European Journal of Cancer. 2024-10-01
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
Alexander G Goglia, Mohammed Alshalalfa, Anwar Khan, Danielle R Isakov, Helen Y Hougen
Journal of the National Cancer Institute. 2024-09-10

Press Mentions

Plenary 2 Explores Definitions, Treatment Modalities for Oligometastatic DiseaseAugust 8th, 2022
Radiation Oncology Appointments Plummeted in the COVID-19 Pandemic—but Seem to Be Rising AgainMay 29th, 2020